A carregar...
Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
BACKGROUND: Alectinib is a highly selective tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK) and provided a significantly prolonged progression-free survival compared with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) harboring rearrangements of the ALK gene....
Na minha lista:
| Publicado no: | Surg Case Rep |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Berlin Heidelberg
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5845085/ https://ncbi.nlm.nih.gov/pubmed/29524063 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40792-018-0430-7 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|